We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.44%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$553M
AUM Growth
+$22M
Cap. Flow
-$5.91M
Cap. Flow %
-1.07%
Top 10 Hldgs %
30.71%
Holding
131
New
7
Increased
28
Reduced
30
Closed
10

Top Buys

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$5.16M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$4.22M
3
AKRX
Akorn Inc
AKRX
+$3.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.21M
5
ENDP
Endo International plc
ENDP
+$2.74M

Top Sells

Rank Stock Value
1
CVS icon
CVS Health
CVS
+$6.62M
2
CAH icon
Cardinal Health
CAH
+$6.02M
3
MDVN
MEDIVATION, INC.
MDVN
+$4.7M
4
STJ
St Jude Medical
STJ
+$4.68M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 92.11%
2 Financials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
51
DELISTED
Radius Health, Inc.
RDUS
$3.3M 0.6%
61,000
+21,000
+53% +$1.07M
XENT
52
DELISTED
Intersect ENT, Inc
XENT
$3.25M 0.59%
205,325
– –
NKTR icon
53
Nektar Therapeutics
NKTR
$2.31B
$3.19M 0.58%
12,400
– –
RARE icon
54
Ultragenyx Pharmaceutical
RARE
$2.88B
$3.05M 0.55%
43,000
+15,000
+54% +$957K
NBIX icon
55
Neurocrine Biosciences
NBIX
$17.2B
$2.94M 0.53%
58,000
– –
MRK icon
56
Merck
MRK
$315B
$2.93M 0.53%
49,256
– –
LLY icon
57
Eli Lilly
LLY
$1.05T
$2.81M 0.51%
35,000
– –
NVDQ
58
DELISTED
Novadaq Technologies Inc.
NVDQ
$2.66M 0.48%
230,000
-40,000
-15% -$434K
ELV icon
59
Elevance Health
ELV
$80.9B
$2.58M 0.47%
20,600
+6,600
+47% +$852K
TMO icon
60
Thermo Fisher Scientific
TMO
$198B
$2.54M 0.46%
16,000
-4,000
-20% -$616K
QGENF
61
DELISTED
QIAGEN NV
QGENF
$2.51M 0.45%
91,500
– –
MGNX icon
62
MacroGenics
MGNX
$285M
$2.48M 0.45%
83,000
– –
PRTA icon
63
Prothena Corp
PRTA
$453M
$2.46M 0.44%
41,000
+10,000
+32% +$537K
ALKS icon
64
Alkermes
ALKS
$8.79B
$2.42M 0.44%
51,500
-14,000
-21% -$666K
AGIO icon
65
Agios Pharmaceuticals
AGIO
$2.36B
$2.38M 0.43%
45,000
+9,000
+25% +$392K
HCA icon
66
HCA Healthcare
HCA
$82.3B
$2.36M 0.43%
31,200
-12,500
-29% -$957K
ZLTQ
67
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$2.35M 0.43%
60,000
– –
SGEN
68
DELISTED
Seagen Inc. Common Stock
SGEN
$2.32M 0.42%
43,000
-25,000
-37% -$1.19M
ANGO icon
69
AngioDynamics
ANGO
$558M
$2.28M 0.41%
130,000
-21,400
-14% -$347K
IPXL
70
DELISTED
Impax Laboratories, Inc.
IPXL
$2.25M 0.41%
95,000
– –
ICPT
71
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.22M 0.4%
13,500
– –
BIB icon
72
ProShares Ultra NASDAQ Biotechnology
BIB
$84.1M
$2.21M 0.4%
45,500
+25,000
+122% +$1.19M
HZNP
73
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.12M 0.38%
117,000
– –
EGRX
74
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$2.03M 0.37%
+29,000
New +$1.61M
GMED icon
75
Globus Medical
GMED
$10.5B
$1.98M 0.36%
87,700
– –
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2016 Portfolio in Review

As of Q3 2016, Bellevue Group held 131 positions worth $553M, up 4.1% from $531M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group's Q3 2016 filing shows 7 new, 28 increased, 30 reduced and 10 closed positions. Its largest new stake was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M. The largest sale was CVS Health, an estimated $6.62M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier, followed by Financials.

  • Bellevue Group's largest Q3 2016 buy was Insys Therapeutics, Inc.: 115,000 shares worth $1.36M.
  • Bellevue Group added most to Viatris in Q3 2016, an estimated $5.16M increase.
  • Bellevue Group's biggest Q3 2016 reduction was CVS Health, cutting an estimated $6.62M.
  • Bellevue Group fully exited MEDIVATION, INC. in Q3 2016, selling an estimated $4.7M.
  • Bellevue Group's ten largest holdings make up 31% of its $553M portfolio in Q3 2016.
  • Bellevue Group opened 7 new positions and closed 10 in Q3 2016.
  • Bellevue Group's portfolio value rose 4.1% quarter-over-quarter to $553M.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.